TRIM56

Across TCGA pan-cancer cohorts, TRIM56 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of TRIM56’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TRIM56 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRIM56 is over-expressed in tumor, although a few such as UCEC and BRCA show the opposite, repressed pattern.

LIHC, KIRC, and STAD are the cancer types where TRIM56 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRIM56 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Female	II,III,IV	+1.395	<.001	9	view →
KIRC	Male	All	+0.543	<.001	9	view →
STAD	All	II,III,IV	+0.844	<.001	8	view →
KIRP	All	All	+0.425	.005	7	view →
UCEC	All	All	−1.299	<.001	6	view →
HNSC	Male	All	+0.718	<.001	6	view →
BRCA	Female	II,III,IV	−0.517	<.001	6	view →
THCA	All	All	−0.276	.001	6	view →
CHOL	All	All	+2.282	<.001	5	view →
LUSC	All	All	−0.433	<.001	4	view →
BLCA	Male	III,IV	−0.682	.005	3	view →
ESCA	All	All	+0.918	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

TRIM56–LIHC

Open the LIHC breakdown →